BioSpace News Archive

NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its fourth quarter and fiscal year 2023, for the period ended December 31, 2023, on Tuesday, April 9, 2024, after the close of the market.

Rapafusyn Pharmaceuticals is pleased to announce two upcoming presentations at Cambridge Health Institute’s 12th Annual Oral Peptides & Macrocyclics Conference, April 1 – 4 in San Diego.

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 23rd Annual Needham Virtual Healthcare Conference.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, announced that effective March 27, 2024, the Compensation Committee of DermTech’s Board of Directors granted an aggregate of 26,240 restricted stock units to eight new employees under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45 p.m. Eastern Time.

Zomedica Corp., a veterinary health company offering point-of-care diagnostic and therapeutic device products for equine and companion animals, reported consolidated financial results for the fourth quarter and year-ended December 31, 2023.

G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for 3,000 shares of G1’s common stock and 1,500 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

Arrowhead Pharmaceuticals, Inc. announced that as an inducement to entering into employment with the Company, on March 30, 2024, the Company’s Board of Directors approved “inducement” grants to 32 new employees under Rule 5635 of the NASDAQ Listing Rules.

Zoetis Inc. (NYSE: ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors.